Сравнение методов
Просматривайте выбранные методы рядом; строки с различиями подсвечены.
| Многоцентровое клиническое исследование III фазы× | Исследование IV фазы× | |
|---|---|---|
| Область | Эпидемиология | Эпидемиология |
| Семейство | Process / pipeline | Process / pipeline |
| Год появления≠ | 1940s–1990s (formalized through ICH harmonization ~1990s) | Formalised 1970s–1990s (ICH E3 guideline 1994) |
| Автор метода≠ | Codified through ICH E9 guideline (1998) and decades of regulatory practice (FDA, EMA) | Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks) |
| Тип≠ | Confirmatory interventional study design | Post-marketing observational or interventional study |
| Основополагающий источник≠ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 | International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat. link ↗ |
| Другие названия | Phase III multicenter RCT, confirmatory multicenter trial, Phase 3 multicenter study, pivotal multicenter trial | post-marketing surveillance study, post-approval study, Phase 4 study, PMS study |
| Связанные≠ | 6 | 5 |
| Сводка≠ | A multicenter Phase III clinical trial is the definitive confirmatory study that tests whether a new intervention produces a clinically meaningful benefit over a comparator in a large, representative patient population enrolled at two or more independent research sites. It is the primary evidence basis for regulatory approval by agencies such as the FDA and EMA, combining the statistical power of large samples with the external validity gained from geographic and demographic diversity across sites. | A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life. |
| ScholarGateНабор данных ↗ |
|
|